Parkinson’s disease (PD) is well known to be a chronic and progressive neurodegenerative disease produced by a selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. The main clinical features of PD include tremor, bradykinesia, rigidity and postural instability. The biochemical and cellular alterations that occur after 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) are remarkably similar to that seen in idiopathic PD. In this review, we discuss the therapeutic effect of Poly (ADP-ribose) polymerase (PARP) inhibitor and anti-convulsant drug against dopaminergic neuronal cell loss in an MPTP model of PD. This review may lead to a much better understanding of PD as well as provide clues to novel targets for therapeutic interventions in PD patients.